TECHNOLOGICAL INNOVATION FOR OSTEOARTHROSIS THERAPY TREATMENT OF AFFECTED JOINTS
Innovative treatments based on linear hyaluronic acid with a high degree of viscosity for joints affected by OA
Flexylink 4
Linear Hyaluronic Acid 2% (HA obtained from biofermentation) EU Classification: Medical Device Class III HA Molecular Chain : Linear Origin: Biofermentation (Streptococcus Equi) Volume (pre-filled syringe): 4ml Molecular Weight: 1500 KDa HA Concentration: 80mg/4ml (2%) Dosage: 2 annual therapies with 2-3 injections one every 15 days Indications: Treatments for all joints Packaging: Airless System (High Safety Profiles)